IRE ISTITUTO NAZIONALE TUMORI REGINA ELENA ISG ISTITUTO DERMATOLOGICO SAN GALLICANO
ISTITUTI DI RICOVERO E CURA A CARATTERE SCIENTIFICO

UOC Acquisizione Beni e Servizi

Il dirigente della UOC Acquisizione Beni e Servizi

in virtù della delega conferita con deliberazione N°327/2025

HA ASSUNTO LA PRESENTE DETERMINAZIONE

N. 756 del 11/08/2025

OGGETTO: Affidamento, ai sensi dell'art. 50, comma 1, lett. b) del D. Lgs. n. 36/2023, fornitura servizio di consulenza per la produzione di anticorpo coniugato con cantaridina alla Società Proteogenix. Fondo PNRR-MUR cod. IFO 24/18/G/50, responsabile Dr.ssa E. Migliano. CUP-B63C22000650007 CIG- B7D791E0DF.

Esercizi/o e conto 2025-502020197 Centri/o di costo 3010250

- Importo presente Atto: € 15.810,86

- Importo esercizio corrente: € 15.810,86

Budget

- Assegnato: € 300.000,00

- Utilizzato: € 280.437,94

- Residuo: € 3.751,20

Autorizzazione n°: 2025/ ABS SAR 129

Servizio Risorse Economiche: **Giovanna Evangelista**

UOC Acquisizione Beni e Servizi Proposta n° DT-780-2025

L'estensore

Daniela Kolziu

Il Responsabile del Procedimento

Barbara Filipponi

Il Dirigente della UOC Acquisizione Beni e Servizi

Giuseppe Navanteri

La presente determinazione si compone di n° 7 pagine e dei seguenti allegati che ne formano parte integrante e sostanziale:

Allegati nr. 20; nota protocollata, relazione del servizio da svolgere, preventivo della società.

Il Dirigente della UOC Acquisizione Beni e Servizi

Visto il Decreto Legislativo 30 dicembre 1992, n. 502 e ss.mm.ii.;

Visto il Decreto Legislativo 16 ottobre 2003, n. 288 e ss.mm.ii.;

Vista la Legge Regionale 23 gennaio 2006, n. 2;

Visto il Decreto Legislativo 31 marzo 2023, n. 36 ed integrato e modificato con Decreto Legislativo del 31 dicembre 2024, n.209;

Visto l'Atto Aziendale adottato con deliberazione IFO n.153 del 19.02.2019, ed approvato dalla Regione Lazio con DCA n. U00248 del 02.07.2019, modificato e integrato con deliberazioni n. 1254 del 02.12.2020, n. 46 del 21/01/2021 e n. 380 del 25.03.2021, approvate dalla Direzione Salute ed Integrazione Sociosanitaria della Regione Lazio, con Determinazione n. G03488 del 30.03.2021;

Visto il Decreto del Presidente della Regione Lazio n. T00015 del 12 febbraio 2025 avente ad oggetto "Nomina del Direttore Generale dell'Azienda Sanitaria Locale dell'IRCCS Istituti Fisioterapici Ospitalieri (Art. 8, comma 7 bis, della legge regionale 16 giugno 1994, n. 18 e s.m.i.)";

Vista la deliberazione n. 160 del 18.02.2025 di presa d'atto dell'insediamento del Direttore Generale dell'IRCCS Istituti Fisioterapici Ospitalieri Dott. Livio De Angelis;

Vista la deliberazione n. 293 del 31.03.2025 con la quale il Dott. Massimo Armitari è stato nominato Direttore Amministrativo degli Istituti Fisioterapici Ospitalieri (IFO);

Vista la deliberazione n. 367 del 23 aprile 2024 con la quale la Dott.ssa Costanza Cavuto è stata nominata Direttore Sanitario f.f. degli Istituti Fisioterapici Ospitalieri;

Visto il D.M. del Ministero della Salute del 20 giugno 2024 di conferma del riconoscimento del carattere scientifico dell'IRCCS di diritto pubblico a Istituti Fisioterapici Ospitalieri (IFO) relativamente alla disciplina di "oncologia" per l'Istituto Nazionale Tumori Regina Elena (IRE) e alla disciplina di "dermatologia" per l'Istituto Santa Maria e San Gallicano (ISG);

Vista la deliberazione n.877 del 29.10.2024 ad oggetto: "Nomina della Prof.ssa Maria Concetta Fargnoli quale Direttore Scientifico dell'Istituto Santa Maria e San Gallicano (ISG).";

Vista la deliberazione n.171 del 28.02.2025 avente ad oggetto: "Nomina del Prof. Giovanni Blandino, Direttore della UOC Ricerca Traslazionale Oncologica, quale Direttore Scientifico IRE facente funzioni, a decorrere dal 01.03.2025.";

Vista la deliberazione n. 327 del 3 aprile 2025 di attribuzione delle deleghe ai Dirigenti del Ruolo Professionale, Tecnico e Amministrativo da parte del Direttore Generale degli IFO;

Vista la deliberazione n. 303 del 01 aprile 2025 che nomina come responsabile unico del procedimento/progetto (RUP) per le procedure di gara in essere e per gli appalti in esecuzione di competenza della UOC Acquisizione Beni e Servizi l'Ing. Giuseppe Navanteri;

Visto il Decreto Legislativo n. 36/2023 e successive modifiche, integrazioni e il correttivo Decreto Legislativo n. 209/2024;

Premesso che con deliberazione n. 102 del 04/02/2025, è stato accettato il finanziamento disposto dall'Università di Siena PNRR-MUR, per lo svolgimento del progetto di ricerca dal titolo: "La cantaridina derivante da coleotteri meloide come potenziale agente terapeutici per il trattamento dei tumori della pelle: progettazione di un anticorpo farmaco-coniugato", cod. IFO 24/18/G/50, responsabile Dr.ssa E. Migliano;

Considerato che, con nota protocollo n. 10791 del 17/07/2025, è pervenuta alla codesta UOC la richiesta di acquisto di un servizio di consulenza per la produzione di anticorpo coniugato con cantaridina all'operatore economico Proteogenix, da utilizzare in studi di internalizzazione su linee cellulari tumorali, formulata dalla Dott.ssa E. Migliano;

Preso atto del parere favorevole del Direttore Scientifico dell'Istituto San Gallicano apposto in calce alla richiesta citata;

Esperiti i controlli sulla richiesta presentata dal responsabile del progetto;

Tenuto conto che, con determinazione nr. 264 del 08/03/2025 veniva affidato parte del servizio di consulenza per il progetto di realizzazione di un ADC (Antibody-Drug Conjugate) contenente cantaridina per un importo pari ad € 16.500,00 iva esclusa;

che il servizio di consulenza è stato affidato mediante due distinti affidamenti, in quanto il servizio oggetto della presente determinazione, richiesto con nota prot. n. 10791 del 17/07/2025, risulta propedeutico al corretto svolgimento del servizio già affidato all'operatore economico Proteogenix con determinazione n. 264 del 08/03/2025 e si sostanzia in:

- Progettazione della strategia di coniugazione anticorpo-farmaco;
- Produzione e purificazione dell'ADC;
    - Fornitura del prodotto finale in quantità pari a 2,5 mg(purificato) idoneo per studi in vitro;
- (Opzionale: eventuale caratterizzazione analitica preliminare dell'ADC);

Rilevato che l'importo presunto è inferiore alla soglia di cui all'art. 14 del D. Lgs. 36/2023 e che rientra nei limiti di valore previsti dall'art. 50 del D. Lgs. 36/2023 per le procedure di affidamento diretto;

Considerato che è stato verificato l'insussistenza di una convenzione attiva stipulata da Consip S.p.A. avente ad oggetto il servizio da acquisire;

che, è stata avviata la fase istruttoria della procedura in oggetto mediante "trattativa diretta" con RDO n. 5540223, inviando una formale richiesta di offerta sulla piattaforma Mepa all'operatore economico Proteogenix;

Preso atto che, il RUP l'offerta economica presentata dall'operatore economico sopracitato pari ad € 12.963,00 iva esclusa è stata ritenuta congrua per l'acquisto de quo;

Considerato che tutti gli allegati amministrativi richiesti per la procedura in questione sono stati regolarmente restituiti, tramite la piattaforma Mepa;

Ritenuto quindi, necessario e opportuno di procedere all'affidamento diretto, ai sensi dell'art. 50 comma 1, lett. b) del D. Lgs. 36/2023, per la fornitura del servizio di consulenza per la produzione di anticorpo coniugato con cantaridina, alla Società Proteogenix;

Considerato che, ai sensi dell'art. 53 comma 4 del D.Lgs n. 36 del 2023 è stata richiesta la "garanzia definitiva" nella misura del 5% dell'importo contrattuale, a scelta del

contraente sotto forma di cauzione o fideiussione con le modalità previste dall'articolo 106 del medesimo decreto;

Considerato che, per espressa disposizione dell'art. 55, comma 2, del D.Lgs. 36/2023, i termini dilatori per la stipula del contratto, previsti dall'articolo 18, commi 3 e 4 del medesimo decreto, non si applicano agli affidamenti di contratti il cui importo è inferiore alle soglie di rilevanza europea;

Considerato che saranno garantiti tutti gli adempimenti ex art. 3 della legge n. 136/2010 (tracciabilità dei flussi finanziari);

Considerato ai sensi dell'art. 18, comma 1, del D. Lgs. 31 marzo 2023, n. 36, trattandosi di affidamento ai sensi dell'art. 50 del medesimo decreto, la stipula del contratto potrà avvenire mediante corrispondenza secondo l'uso commerciale, consistente in un apposito scambio di lettere, anche tramite posta elettronica certificata o sistemi elettronici di recapito certificato qualificato ai sensi del regolamento UE n. 910/2014 del Parlamento europeo e del Consiglio del 23 luglio 2014;

Considerato che, la spesa complessiva di € 15.814,90 Iva compresa, graverà sul Fondo PNRR-MUR cod. IFO 24/18/G/50, responsabile Dr.ssa E. Migliano che presenta la necessaria disponibilità;

Precisato che tutta la documentazione richiamata e non allegata alla presente determinazione è reperibile agli atti della UOC Acquisizione Beni e Servizi;

Attestato che il presente provvedimento, a seguito dell'istruttoria effettuata, nella forma e nella sostanza è totalmente legittimo e utile per il servizio pubblico, ai sensi dell'art. 1 della legge 20/94 e successive modifiche, nonché alla stregua dei criteri di economicità e di efficacia di cui all'art. 1, primo comma, della legge 241/90, come modificata dalla legge 15/2005;

Determina

per i motivi di cui in narrativa che si intendono integralmente confermati di:

1) affidare, ai sensi dell'art. 50, comma 1, lett. b) del D. Lgs. n. 36/2023, la fornitura del servizio di consulenza per la produzione di anticorpo coniugato con cantaridina all'operatore economico Proteogenix;

2) far gravare la spesa complessiva di € 15.814,90 Iva inclusa, sul Fondo PNRR-MUR cod. IFO 24/18/G/50, responsabile Dr.ssa E. Migliano che presenta la necessaria disponibilità;

Cod. IFO 24/18/G/50

- assegnato:	€	300.000,00
- utilizzato:	€	280.437,94
- presente atto:	€	15.810,86
- residuo:	€	3.751,20

3) attribuire il costo di produzione alla Contabilità Generale con imputazione al relativo Centro di Costo 3010250 - Conto 502020197;

La UOC Acquisizione Beni e Servizi curerà tutti gli adempimenti per l'esecuzione della presente determinazione.

Il Dirigente della UOC Acquisizione Beni e Servizi

Giuseppe Navanteri

Documento firmato digitalmente ai sensi del D.Lgs 82/2005 s.m.i. e norme collegate

Roma, 16/07/2025

Alla Direzione Scientifica ISG

All'Ufficio ABS

LORO SEDI

Oggetto: Richiesta consulenza per la produzione di anticorpo coniugato con cantaridina.

Si richiede di effettuare un ordine di € 12.963.00 (come da offerta allegata) presso la ditta Protogenix **progettazione e coniugazione di un Antibody-Drug Conjugate (ADC)** da utilizzare in studi di internalizzazione su linee cellulari tumorali.

Il progetto prevede la realizzazione di un ADC contenente **cantaridina** come agente citotossico, coniugata ad anticorpi specifici per **EGFR**, **CD44** e/o altri marcatori di superficie tumorale. L'obiettivo è di sfruttare la specificità di questi anticorpi per veicolare selettivamente il farmaco verso le cellule tumorali, facilitandone l'internalizzazione e riducendo al minimo l'esposizione a tessuti sani.

Il servizio richiesto comprende:

- **Progettazione della strategia di coniugazione** anticorpo-farmaco;
- **Produzione e purificazione dell'ADC**;
- **Fornitura del prodotto finale** in quantità pari a **2,5 mg (purificato)**, idoneo per studi in vitro;
- (Opzionale: eventuale caratterizzazione analitica preliminare dell'ADC).

La spesa graverà su fondi Cod. IFO: 24/18/ G/50 di cui sono la Responsabile.

Istituto Dermatologico San Gallicano - IFO IRCCS
Direttore Scientifico
Prof.ssa Maria Concetta Fargnoli

Responsabile P.I.
Dr.ssa Emilia Migliano
Chirurgo Plastico

Roma, 09/07/2025

Alla Direzione Scientifica ISG

All'Ufficio ABS

LORO SEDI

Oggetto: Richiesta produzione di anticorpo coniugato con cantaridina

Al fine di effettuare studi di internalizzazione di anticorpi/ADC si richiede il servizio di progettazione e coniugazione dell'ADC (Antibody-Drug Conjugate, ADC) che sarà fornito come prodotto terminale di 2.5 mg (purificato). Grazie alla specificità degli anticorpi verso EGFR, CD44 e/o altri marcatori di superfice, sarà possibile veicolare la cantaridina in modo più specifico verso i tumori, concentrandola all'interno delle cellule tumorali grazie all'internalizzazione dell'ADC, e limitando l'esposizione a tessuti e organi sani.

Responsabile della Ricerca (P.I.)

Dr.ssa Emilia Migliano
Chirurgo Plastico

N.Richiesta	MODULO DI RICHIESTA DISPOSITIVI MEDICI PER LA RICERCA SCIENTIFICA	IRE ISG
(Spazio Riservato)	Valido per acquisizione di dispositivo medico, presidio medico chirurgico, dispositivo diagnostico, prodotto diagnostico IVR e DPI infungibile	

Data	
Dipartimento	UOC Dermatologia
U.O. / Servizio richiedente	

A) INFORMAZIONI SANITARIE

Tipologia, descrizione e caratteristiche tecniche del dispositivo:

Ragioni di natura tecnica correlate a specifiche indicazioni di natura diagnostica e di risultato che non consentono l'impiego di prodotti con caratteristiche equivalenti e che giustificano la dichiarazione di infungibilità:

Il servizio reso a fronte dell'incarico assegnato alla ditta Protogeniz è infungibile in quanto la produzione del coniugato anticorpo-cantardina è indispensabile per la seconda fase del progetto che prevede il targeting specifico attraverso l'internalizzazione recettore dipendente

B) INFORMAZIONI ORGANIZZATIVE

Codice di repertorio nazionale: .....

Produttore: .....

Fabbisogno presunto in UM: .....

Spesa presunta (IVA esclusa): .....

Durata proposta del contratto di fornitura: .....

Informazioni aggiuntive: .....

.....

.....

C) DICHIARAZIONE DI INFUNGIBILITA'

I sottoscritti, consapevoli delle possibili responsabilità di natura civile, penale, disciplinare e amministrativo-contabile in merito all'attestazione di informazioni false, inesatte od erronee, dichiarano che, per le indicazioni cliniche sopra specificate, non sono disponibili nel repertorio nazionale DM prodotti alternativi con caratteristiche equivalenti, sia in termini prestazionali che funzionali. A tal fine dichiarano che il prodotto richiesto:

- ☐ il prodotto, consistente in materiale di consumo o reagenti (non apparecchiature), è necessario per ultimare ultimare esperimenti ricompresi in un progetto di ricerca in corso (avviato da almeno 60 gg.), ed il ricercatore ha dichiarato che il cambio di prodotto renderebbe necessario ripetere test già effettuati in precedenza, in quantità tali da compromettere i tempi previsti per la sperimentazione.
- ☒ la ricerca appartiene ad una rete coinvolgente, oltre agli IFO, altri centri di ricerca (progetto multicentro), ed il direttore/responsabile del "progetto rete" ha dichiarato esplicitamente che ciascun centro di ricerca deve necessariamente dotarsi di un particolare prodotto commercializzato da determinato unico operatore economico, al fine di non compromettere le finalità della ricerca.
- ☐ il prodotto è stato già utilizzato dall'Istituto o in altri centri nell'ambito di progetti di ricerca analoghi a quello per il quale se ne richiede l'acquisto e, quindi, considerato necessario ai fini della comparabilità dei risultati.
- ☐ la ricerca preveda necessariamente l'utilizzo di un'apparecchiatura (già stabilmente di proprietà degli IFO) ed il prodotto, consistente in materiale di consumo o reagenti da utilizzare con l'apparecchiatura in questione, debba essere necessariamente fornito da un unico operatore economico determinato in quanto il produttore dell'apparec_ chiatura ha certificato sul manuale d'uso che tale prodotto è l'unico compatibile con l'apparecchiatura

Timbro/firma Ricercatore Richiedente

Dr.ssa Emilia Migliano Chirurgo Plastico

Timbro/firma Responsabile Ricerca (P.I.)

Dr.ssa Emilia Migliano Chirurgo Plastico

Timbro/firma Direttore Scientifico

D) Valutazione Direz.ne Scientifica :

- ☐ Massima urgenza
  Priorità piano acquisti anno
- ☐ Urgente
- ☐ Non urgente
- ☐ Programmabile

Istituto Dermatologico San Gallicano - IFO IRCCS

Direttore Scientifico

Prof.ssa Maria Concetta Fargnoli

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !

IRCCS - Istituti Fisioterapici Ospitalieri
Emilia MIGLIANO Tiziana Persichini

DATE: June 24, 2025

IRCCS - ADC SCALE-UP

Your Contact At ProteoGenix:

NAME : Gaëtan MAURER
EMAIL : gmaurer@proteogenix.fr

Crédit Impôt Recherche CIR

Liberté • Égalité • Fraternité
RÉPUBLIQUE FRANÇAISE
MINISTÈRE DE L'ENSEIGNEMENT SUPÉRIEUR ET DE LA RECHERCHE

afaq ISO 9001 Qualité AFNOR CERTIFICATION

afaq ISO 14001 Environnement AFNOR CERTIFICATION

aadlac INTERNATIONAL

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !

ProteoGenix

ProteoGenix is a leading life sciences organization with a strong technical background and a state-of-the-art equipment fleet offering a **one-stop solution from gene synthesis to diagnostics and biotherapeutics**. With more than **20 years of experience**, we account for a unique and customized access to 5 areas of complementary services structured around:

- **Antibody engineering** (Humanization, Affinity Maturation, Bi-specific, ADC, IP free stable cell line development)
- **Antibody characterization** (Sequencing, Kd, ADCC, Stability, Glycosylations, Structure, Aggregation)
- **Monoclonal and polyclonal antibody development** (Hybridoma method and Phage Display)
- **Recombinant protein and antibody production** (E. coli, B. subtilis, Yeast, Insect cells, Mammalian cells)
- **Gene synthesis**
- **Peptide synthesis**

Our interdisciplinary experience in Antibody, Protein, Gene and Peptide and our optimal size structure allow us to deliver carefully validated and characterized reagents meeting our customer's accurate specifications. The final application guides the design of the production strategy in all the steps of our development processes.

The consequence of this strategy is a significant increase in our success rate, in the quality of the reagents and in the reduction of the risk for our customers.

20

20+ years experience

String technical background

Multi-service laboratory

From gene to biotherapeutics or diagnostic kits

Crédit Impôt Recherche CIR

Liberté • Égalité • Fraternité
RÉPUBLIQUE FRANÇAISE
MINISTÈRE DE L'ENSEIGNEMENT SUPÉRIEUR ET DE LA RECHERCHE

afaq ISO 9001 Qualité AFNOR CERTIFICATION

afaq ISO 14001 Environnement AFNOR CERTIFICATION

aadlac INTERNATIONAL

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !



Antibody-Drug Conjugate (ADC) Development Service General Information

- Any client's material and information provided to ProteoGenix shall remain the client's proprietary and confidential information and shall be used by ProteoGenix solely for the purpose of the provision of the services.
- Because ADC development is **complex** and highly **customized**, ProteoGenix offers **step-by-step services** including **milestones (Go / No-Go)** in order to guarantee a safe investment to customers. Each step is confirmed and discussed with customers through **detailed reports** comprising description of experiments, results, discussion & conclusion. Work can be stopped any time and only started or completed steps are invoiced and due.
- For preclinical research use only: the technology used in this project is protected making the commercialization of any ADC subjected to license fees. Beyond preclinical research purposes, the client needs to negotiate license agreements with us.
- **Delivery time** has to be considered as estimated only; it can vary very much depending on projects and it does not reflect any production difficulties, if so encountered. Please be sure that ProteoGenix will do its best to deliver as fast as possible!
- Our quotation is **unique** and should be ordered **as is**. If you plan to order only part of it, please come back to us in order to update the quotation accordingly unless you have a general pricing agreement.

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !

Why ProteoGenix?

Flexible conjugation strategies
Choose between chemical and enzymatic conjugation methods according to your unique needs

Drug diversity and dual drug ADC development
Choose the best drug for animal therapeutic efficacy or opt for dual drug systems thanks to our platform for a synergist treatment

Accelerated antibody production
Speed up ADC development and antibody engineering thanks to our highly productive cell line - XtenCHO (TM)

Extensive bioanalytical capabilities
Characterize DAR values, drug load distribution, % of free drug and antibody, with high accuracy and precision to ensure high success rates during clinical development

Solid track record
Benefit from 20+ years of experience in antibody-drug conjugate (ADC) development and 5 therapeutic ADCs in clinical trial

Vast range of complimentary services
Streamline ADC development thanks to our flexible solutions in antibody discovery (phage display, hybridoma), engineering (affinity, stability), and stable cell line generation

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

Selected References Of Monoclonal Antibodies Developed By ProteoGenix

Patents

- **Italian Endometriosis Foundation**, Italy (2025): https://patents.google.com/patent/WO2025062271A1/en
- **ISAR Bioscience GmbH**, Germany (2024): https://patents.google.com/patent/WO2024160736A1/en
- **Cleveland Clinic**, USA (2024): https://patents.google.com/patent/WO2024254399A2/en
- **University of Birmingham**, UK (2024): https://patents.google.com/patent/WO2024028436A1/en
- **OneChain Immunotherapeutics SL**, Spain (2024): https://patents.google.com/patent/WO2024170627A1/en
- **University of Bern**, Switzerland (2023): https://patents.google.com/patent/WO2024170627A1/en
- **AbnomX BV**, Belgium (2023): https://patents.google.com/patent/WO2023161448A1/en
- **Gyala Therapeutics SL**, Spain (2023): https://patents.google.com/patent/EP4209511A1/en
- **Pictor Ltd**, New Zealand (2022): https://patents.google.com/patent/WO2022039604A1/en
- **Yale University**, USA (2021): https://patents.google.com/patent/WO2021237159A1/en

Publications

- M Vigo et al.,Isoform-specific vs. isoform-universal drug targeting: a new targeting paradigm illustrated by new anti-ICAM-1 antibodies. ***J Drug Targeting*** 33, (4) 562-74 (2025). https://doi.org/10.1080/1061186X.2024.2438884
- M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. ***Front Immunol*** 15, 1520103 (2024). https://doi.org/10.3389/fimmu.2024.1520103
- E Vidal-Calvo et al., Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. ***Nature Communications*** 15, 7553 (2024). https://doi.org/10.1038/s41467-024-51781-0
- Z Li et al., A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice. ***Oncotarget*** 15, 575-87 (2024). https://doi.org/10.18632/oncotarget.28638
- L Kis et al.,Proof of concept for monoclonal antibody therapy in a cellular model of acquired long QT syndrome type 3. ***Am J Physiol Heart Circ Physiol*** 326, H89-95 (2024). https://doi.org/10.1152/ajpheart.00628.2023
- M Marco et al., Two-year post-distraction cartilage-related structural improvement is accompanied by increased serum full length SIRT1. ***Arthritis Research & Therapy*** 26, 106 (2024). https://doi.org/10.1186/s13075-024-03342-5
- A Saviano et al., New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function. ***Ann Rheum Dis*** 82, 1415-28 (2023). https://doi.org/10.1136/ard-2023-224479

- A Villatoro et al., Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. ***Nature Communications*** 14, 12 (2023). https://doi.org/10.1038/s41467-022-35700-9
- A Surribas et al., Monoclonal antibody-based immunosensor for the electrochemical detection of chlortoluron herbicide in groundwaters. ***Biosensors*** 11, (12) 513 (2021). https://doi.org/10.3390/bios11120513
- G Willman et al., Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-thioredoxin antibody. ***J Imm Ther Canc*** 9, (2) 841 (2021). https://doi.org/10.1136/jitc-2021-SITC2021.841
- JP Barnier et al., The minor pilin PilV provides a conserved adhesion site throughout the antigenically variable meningococcal type IV pilus. ***PNAS*** 118, 45 (2021). https://doi.org/10.1073/pnas.2109364118
- H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. ***J Clin Lab Anal*** 35, (4) 23735 (2021). https://doi.org/10.1002/jcla.23735
- N Yacov et al., MOSPD2 is a therapeutic target for the treatment of CNS inflammation. ***Clin Exp Imm*** 201, (2) 105-20 (2020). https://doi.org/10.1111/cei.13448
- PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. ***PNAS*** 117, (8) 4320-27 (2020). https://doi.org/10.1073/pnas.1913810117
- M Fresquet et al., Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. ***J Autoimm*** 106, 102308 (2020). https://doi.org/10.1016/j.jaut.2019.102308
- P Cunha et al., Expansion, isolation and first characterization of bovine Th17 lymphocytes. ***Nature Sci Rep*** 9, 16115 (2019).https://doi.org/10.1038/s41598-019-52562-2
- M Krifa et al., Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving $p16^{INK4A}$ re-expression related to UHRF1 and DNMT1 down-regulation. ***J Exp Clin Canc Res*** 32, 30 (2013).https://doi.org/10.1186/1756-9966-32-30
- E Faure et al., Probable presence of an ubiquitous cryptic mitochondrial gene on the antisense strand of the cytochrome oxidase I gene. ***Biol Direct*** 6, 56 (2011). https://doi.org/10.1186/1745-6150-6-56

Press releases

- **Cizzle Biotech Inc**, UK (2024): antibody which was developed by ProteoGenix by hybridoma against a biomarker and is going to be used in a kit for early-stage lung cancer diagnosis: https://pressat.co.uk/releases/proteogenix-and-cizzle-biotechnology-collaboration-forges-new-paths-in-early-detection-of-lung-cancer-through-innovative-antibody-development-2038c6819534efae0f0b274b6d8c5b86/
- **Trident BioPharm Solutions Ltd**, UK (2021): cocktail of 4 fully human antibodies which were developed by ProteoGenix by phage display of our human libraries, shown to bind and block all major strains of COVID-19: https://drug-dev.com/proteogenix-aseem-healthcare-trident-biopharm-solutions-announce-new-antibody-cocktail-effective-against-major-variants-of-sars-cov-2/

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

QUOTATION N° 20250624-150556489

Date of the quotation : June 24, 2025
Valid until : August 8, 2025

Code	Product Description
MCF-AB-ADC	**Antibody-Drug Conjugate (ADC) development via advanced Site-Specific Chemistry** • **Monoclonal antibody designation:** purified human IgG1 provided by customer • **Drug designation:** Norcantharidin provided by ProteoGenix • **DAR chosen by customer: 4** **NB1:** DAR means Drug-Antibody Ratio i.e. the number of drug molecules per antibody molecule • **Conjugation method:** highly controlled site-specific conjugation on Cysteins => 100% specific + very homogenous + high batch-to-batch reproducibility **STEP II: Recombinant Antibody conjugation to Norcantharidin** **Content:** • Conjugation of antibody in previously defined conditions to achieve a controlled DAR of **4** • Final QC: SDS-PAGE, SEC-HPLC & HIC-HPLC • Delivery of report + antibody samples (8mg conjugated antibody*) • On average via our method >90% of antibody molecules are conjugated to Norcantharidin with the chosen DAR 4 (not guaranteed as can vary very much depending on antibody) * Other quantites possible with extra-price **Material needed from customer:** - 16mg of purified antibody (ideally conc. of at least 1mg/mL in PBS, purity >90%) **Lead time:** 2-3 weeks (may be longer depending on drug availability) **Price:** - EUR 18,500 **Payment conditions:** 50% prepayment before starting this step 50% at step completion

Unit Price	Amount	Disc.	Total
€18,500.00	1	31%	€12,765.00

XFP02DI	**Shipping Costs and Handling fees to Italy** ***By choosing us, you settle on a partner committed to sustainability, using low-CO2 transport solutions, to contribute to a more eco-friendly future!***

Unit Price	Amount		Total	
€99.00	2		€198.00	

Total VAT excluded	**€18,698.00**
Total after Disc.	**€12,963.00**
VAT	
Grand total	**€12,963.00**

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !

HOW TO PLACE AN ORDER :

There are 3 possible ways to place your order.
You just have to **send us your formal purchase order:**

- By fax: +33 (0)9 78 53 36 90
- By email: order@proteogenix.fr
- By regular mail: ProteoGenix SAS, 19 rue de La Haye, 67300 SCHILTIGHEIM, FRANCE

Note: Please use the **"CUSTOMER PURCHASE ORDER FORM"** below if you do not have an official one from your administration
In any case, please make sure it specifies:

- The name of the purchaser
- The price offer/quotation number
- The billing address
- The delivery address
- The intracommunity V.A.T number if applicable

Please join this offer filled in, initialled and signed

USEFUL INFORMATION ABOUT OUR SERVICES :

- Our products are intended for **laboratory research use only**
- For EU customers, VAT registration number will be necessary for VAT exclusive order.
- By placing this order, you agree with the **Terms and Conditions** which can be found below and at https://www.proteogenix.science/terms-of-sale/
- **Delivery time** has to be considered as estimation only; it does not reflect any production difficulties, if so encountered. Please be sure that ProteoGenix will do its best to deliver as fast as possible!

USEFUL INFORMATION ABOUT PROTEOGENIX :

- SIRET : 444 773 717 00061
- EU VAT registration number : FR27444773717
- Company registration number : RCS Strasbourg 03 B 124
- Legal Status : Simplified Joint Stock Company
- DUNS Number : 266554091
- NCAGE : FBFY6

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ACCEPTED PAYMENT TYPES

BANK TRANSFER IN EUROS

1. For International customer :

Beneficiary Bank account name :
PROTEOGENIX SAS
Bank name: Caisse d'Epargne Grand Est Europe
Bank Address : 1 Av du Rhin,
67925 STRASBOURG Cedex 9
IBAN: FR76 1513 5090 1708 0032 9752 126
Swift / BIC code: CEPAFRPP513

2. For French customer :

Beneficiary Bank account name : PROTEOGENIX
Branch name: CCM illkirch Graffenstaden
Bank Address : 144 Route de Lyon
67401 ILLKIRCH CEDEX
IBAN: FR76 1027 8012 2700 0305 8624 557
Swift / BIC code: CMCIFR2A

BANK TRANSFER IN USD :

Beneficiary Bank account name :
SA PROTEOGENIX
Bank name : Banque Populaire Alsace Lorraine Champagne
Bank Address : 205 route de Lyon
67400 ILLKIRCH GRAFFENSTADEN
IBAN : FR76 1470 7500 2067 6291 2439 008
Bank code/ Routing Code : 10278
Sort Code : 50020
Account Number : 67629124390
Swift / BIC Code : CCBPFRPPMTZ

Please pay all associated bank fees
(yours+ intermediary)

CREDIT CARD :

If you wish to pay by credit card, please mention this in your order. Our accounting department will send you a secured payment link by email.

CHEQUE :

French bank cheques accepted without fees.
International cheques accepted only if customer covers our 25 euros banking fees. In such case, customer should inform ProteoGenix prior to placing his order, giving us the opportunity to adjust the quotes pricing accordingly.
Please send your cheque to the address below :
ProteoGenix SAS, 19 rue de La Haye, 67300 SCHILTIGHEIM, France

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

CUSTOMER PURCHASE ORDER FORM

The formal PO from your administration is preferred, please, use this PO form only if you don't have any.

Quotation number: 20250624-150556489

Date:

Purchase Order Number:

VAT number (for EU customers):

Authorized Purchaser Name and Title:

Phone number:

Billing email Address:

SHIP TO:

Company / Name :

Address :

Zip Code :

City :

Country :

BILL TO (IF DIFFERENT FROM "SHIP TO") :

Company / Name :

Address :

Zip Code :

City :

Country :

Quote#	Product Description	Total Price
20250624-150556489	IRCCS - ADC scale-up	€12,963.00

By submitting this Purchase Order, customer understands and agrees that all products purchased from ProteoGenix are to be used exclusively for laboratory research use only and confirms he has read and accepted our Terms and Conditions which can be found at: https://www.proteogenix.science/terms-of-sale/

I hereby declare and confirm that I am an authorized purchaser and I wish to order quotation n°**20250624-150556489**

Signature:

ProteoGenixSAS
19 rue de La Haye
67300 SCHILTIGHEIM - FRANCE

Tel: +33 (0)3 90 20 54 70
Fax: +33 (0)978 53 36 90

Mail: contact@proteogenix.fr
Web: www.proteogenix.science

ProteoGenix
Accelerate your therapeutic research !

STANDARD TERMS AND CONDITIONS OF SALE

I - OBJECT, ACCEPTANCE, AND SCOPE OF THE GENERAL TERMS AND CONDITIONS OF SALE

1. These general terms and conditions of sale ("GTCS") aim to govern the contractual relationships between the company ProteoGenix and its clients within the scope of its professional activities. They apply without exception to all sales of goods and/or services as defined in the quotations or sales agreements provided by the company ProteoGenix to its clients, and to which these conditions are attached.

2. Any order for goods and/or services by the client implies their unconditional acceptance and their full and complete adherence to these general terms and conditions of sale, which prevail over any other document from the client, unless an unequivocal written agreement is provided by the authorized representative of ProteoGenix.

II - ORDERS

1. The orders will only be taken into account by the company ProteoGenix upon the signing of the purchase order by the authorized representative of the client. Any order is binding to ProteoGenix only after its written acceptance by ProteoGenix.
2. Any order accepted by ProteoGenix is irrevocable and cannot be cancelled by the client except with the written agreement of ProteoGenix and subject to the compensation for the total losses suffered by ProteoGenix, including loss of profits.
3. Each purchase order must include the order number, the intracommunity VAT or UK VAT registration number of the client if applicable, catalog references, product/service descriptions, quantities, delivery address, billing address, as well as the name and telephone number of a contact person at the client's end. ProteoGenix accepts no responsibility for consequences arising from errors, inaccuracies, or omissions on the purchase order made by the client.
4. The purchase order must include a detailed delivery address along with all relevant information for the delivery, such as, but not limited to: reception opening hours, access codes, vehicle size limits, recipient's contact phone number, etc. ProteoGenix accepts no responsibility for consequences resulting from incomplete or inaccurate delivery information provided on the purchase order by the client.
5. All additional costs incurred due to the production of replacements, new shipments, or modified shipments requested by the client as a result of an error on the purchase order will be the responsibility of the client.
6. If the client intends to make a change during the execution of an order, they must submit a written request to ProteoGenix and await its written approval.
   In the event of approval, ProteoGenix reserves the right to modify the financial terms accordingly.
7. ProteoGenix reserves the right to decide whether to continue or interrupt an order in the event of unexpected technical problems, such as (but not limited to): non-immunogenic or toxic antigens, non-expressed proteins, challenging cloning, etc. Any interruption will be justified by ProteoGenix, and only the stages that have been started or completed will be invoiced.
8. ProteoGenix does not provide any of its protocols but only raw data at the end of certain stages or at the completion of the service.

III - PRICES

1. All prices, unless otherwise stated, are in euros.
   Payments must be made in euros unless there is a written agreement between the client and ProteoGenix for the use of US dollars or any other currency.
2. The prices are those specified in the quote or, in the absence of one, those listed in the current catalogs or on the ProteoGenix website.
   They may be changed without prior notice, and ProteoGenix accepts no responsibility for printing errors in its catalogs or on its website.
3. The prices exclude all types of taxes, customs duties, shipping, and handling fees.
   Shipping and handling fees will be determined based on the order value, size and weight of the shipment, destination, and chosen mode of transport.

IV - PAYMENT CONDITIONS

1. Subject to any other agreement between ProteoGenix and the client, the payment terms are 30 days from the date of invoicing by ProteoGenix, even if the delivery or performance has not occurred, and the ownership of the products has not been transferred to the client.
2. As an exception, new clients without an established account with ProteoGenix must settle their purchases by making an advance payment and attaching their payment to the order. The same applies to orders for customized items.
3. No discount is applicable in the case of early payment.
4. ProteoGenix accepts the following modes of payment::
   - Bank transfers: In the case of invoicing bank transfer fees to ProteoGenix, these fees will be billed to the client without further notice.
   - Credit cards.
   - Cheques: ProteoGenix only accepts French cheques. However, international cheques may be accepted if the client agrees to cover the bank fees of 25 euros. In this case, the client must inform ProteoGenix of their intention to pay by international cheque before placing an order so that the additional cost can be added to the client's quote and invoice.
5. In the absence of full payment by the due date, penalties based on the semi-annual refinancing rate of the European Central Bank in effect on January 1st or July 1st, depending on the order date, plus 10 points, will be applied from the day following the payment date stated on the invoice. Late payment penalties are due without the need for a reminder.
   In accordance with Article D. 441-5 of the Commercial Code, in case of late payment, the client will automatically owe ProteoGenix, in addition to late payment penalties, a lump-sum indemnity for recovery costs of 40 euros.
6. In the event of the absence of full payment of an invoice by its due date, ProteoGenix may, by operation of law, terminate the sale eight days after a notice has been ineffective, without prejudice to any potential claims for damages.
   Similarly, the failure to make full payment of an invoice by its due date will result in the immediate maturity of all invoices from the client.

V - TRANSPORT RELATED RISKS

The transfer of risks for the sold goods occurs upon their delivery to the carrier.

Unless there is a written agreement to the contrary accepted by both parties, the goods travel at the client's risk, regardless of the mode of transport.

The transportation of the goods is solely the responsibility of the client, and at their expense. It is the client's responsibility to obtain any insurance they deem necessary.

VI - DELIVERY TIMES

The deadlines mentioned on the website as well as in ProteoGenix's quotations are purely indicative in nature.
These deadlines may be subject to significant variations due to the uncertainties inherent in the production of proteins, antibodies, peptides, and genes ordered by the client.

ProteoGenix will make every effort to meet the indicative deadlines stated on its website and in its quotations.

However, due to the unpredictable nature of biological research, ProteoGenix accepts no responsibility for delivery delays, regardless of the cause.

VII - RECEPTION AND STORAGE BY THE CLIENT

1. In the event of damage, loss, or shortage, it is the responsibility of the client to make specific and justified reservations on the transport document and to address their claims to the last carrier in accordance with Article L.133-3 of the Commercial Code.
   The client must inform ProteoGenix within 8 days of receipt, through email, fax, or mail.
   ProteoGenix shall not be held responsible for any losses, damages, or quality alterations that are attributed to the transportation process.
2. The products must be inspected upon receipt and stored as indicated on the labels or technical sheets provided with the product. If no instructions are provided (typically for customized services), it is the sole responsibility of the client to test different storage conditions and use the one that best suits the product and its preservation.
3. ProteoGenix will ensure that all products meet the agreed specifications before shipping.
   However, if, upon inspection by the client, it is found that the products do not meet the agreed specifications, claims regarding their non-conformity to the ordered products must be made by registered letter with acknowledgment of receipt or hand-delivered letter with acknowledgment of receipt within eight days following the delivery of the products.
   After this period, no claims will be accepted, regardless of the alleged failure, and the client must pay the full price.
4. In addition, these claims must specify the alleged defects and provide any justification regarding the reality and significance of the alleged defects, non-conformities, and deficiencies. This includes returning, at the client's expense and within the same eight-day period, the products deemed non-conform by an appropriate means of transportation.
   ProteoGenix will only replace the products or refund the client under these strict conditions.
5. ProteoGenix will not replace any product nor refund the client in the case of inappropriate storage by the client.

VIII - LIABILITY

1. ProteoGenix cannot be held responsible for the non-performance of any of its obligations resulting from a force majeure event. Force majeure events include, but are not limited to, labor disputes, supplier delivery delays, wars, embargoes, pandemics, fires,

VIII - LIABILITY

1. ProteoGenix cannot be held responsible for the non-performance of any of its obligations resulting from a force majeure event. Force majeure events include, but are not limited to, labor disputes, supplier delivery delays, wars, embargoes, pandemics, fires, cataclysms, events affecting transportation means, energy issues, as well as unforeseeable internal organizational circumstances within the company (illness, equipment failure, etc.).
2. All products and services marketed by ProteoGenix are exclusively intended for in vitro research and are not approved for therapeutic or diagnostic purposes.
   It is the sole responsibility of the client to qualify/validate the products for any other use.
   ProteoGenix accepts no responsibility for damages resulting from the use of its products for therapeutic or diagnostic purposes, as well as for in vivo use, regardless of the cause and origin of such damages.
3. The products should only be used by the client's trained personnel, following appropriate laboratory practices.
   Some products may contain components of animal origin.
   As the risks associated with the use of our products may be unknown or difficult to assess, the absence of a warning does not imply that the use of the product is not dangerous.
4. The client commits to providing ProteoGenix, under their responsibility, with all essential information regarding the biological risks associated with the supplied materials and any specific handling procedures to be followed by personnel, if applicable.This information must be provided at the beginning of the project.
5. ProteoGenix will not be held responsible for claims related to improper use or inappropriate storage of the products or for any misinterpretation of result analysis.
   The client is responsible for determining the optimal storage conditions for the products, and ProteoGenix will not be liable for improper storage.

IX - WARRANTIES

1. ProteoGenix cannot provide any warranty regarding the use of its products or services for a specific application, unless otherwise agreed.
   i. The success of monoclonal and polyclonal antibody development programs heavily depends on the nature of antigens, and ProteoGenix, therefore, cannot guarantee:
      - The specificity of antibodies (background noise and cross-reactivity)
      - The sensitivity of antibodies (detection threshold and affinity)
      - The appropriate use of antibodies in all applications (e.g., antibodies may not function in western blot, flow cytometry, ELISA, IHC, etc.).
      - The immune response of animals.

   ii. Regarding protein production services, ProteoGenix cannot guarantee:
      - That cloning into its expression vectors is always achievable.
      - The production yield and the quality of the protein (purity, folding, degradation).
      - That the expression of the protein in its strains is always possible.
      - The absence of variations in yield between expression tests and the production scaling-up stage.
2. Unless otherwise specified, all peptide quantities mentioned on our website and in all our documents, including but not limited to the quotation, certificate of analysis, packing list, and invoice, are gross weights. The gross weight includes the weight of the peptide, residual amino acids, adherent water, and salts (e.g., TFA).
3. The client understands and agrees that the products are of an experimental nature and are provided without any warranty, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, suitability for any safety purpose, utility, effectiveness, purity, safety, non-toxicity, accuracy, and/or non-infringement.
   In particular, ProteoGenix and its affiliates, directors, officers, employees, or agents make no representation or warranty that the use of the products will not infringe on any patent, copyright, trademark, or any other intellectual property right of a third party.
4. The client is responsible for obtaining all third-party intellectual property rights required for the use of the products.
5. The client agrees to defend, indemnify, and hold ProteoGenix, its affiliated companies, as well as their respective officers, directors, agents, employees, and shareholders, harmless from any third-party claims, liability, demand, damages, expenses (including reasonable attorney and expert fees), and losses in the event of death, injury, illness, or property damage, infringement or misappropriation of intellectual property, or any other harm or damage resulting from:
   i. the client's violation of any of its representations, warranties, or commitments,
   ii. any use, reproduction, sale, or importation of the products by the buyer and/or its distributors or customers.

X - INSURANCE

The client must, at their own expense, obtain comprehensive general liability insurance, including property liability insurance, property and personal damage insurance, as well as liability insurance, and maintain this coverage for a period and for amounts which are commercially reasonable.

XI - INTELLECTUAL PROPERTY

1. After full payment of the service, ProteoGenix grants the client the broadest rights to use, reproduce, and commercially exploit the peptides, genes, proteins, monoclonal/polyclonal antibodies, and humanized antibodies developed.
   These rights are granted without territorial or time limitations and without financial consideration other than the contractually agreed-upon development cost unless otherwise specified.
   This includes the hybridoma cell lines producing the developed monoclonal antibodies.

2. Due to the very low but nevertheless existing probability that the same antibodies could be independently developed in the context of other projects or by other individuals, these rights are always granted on a non-exclusive basis.
3. These rights are not granted in the case of stable cell lines developed by ProteoGenix expressing a recombinant antibody/protein. In this case, a separate commercial license agreement must be concluded before the start of the project.
4. The client is responsible for obtaining all third-party intellectual property rights required for the use of the products, regardless of the nature of such use.
5. Property of ProteoGenix): The client acknowledges that ProteoGenix owns certain materials and processes, including but not limited to any reagent, library, cell line, plasmid, protocol, results, formulas, inventions, patents, know-how, and technologies as of the date of the conclusion of this contract, which are used for the provision of the service ("Property of ProteoGenix"). The client agrees that all improvements, modifications, or enhancements directly and specifically related to the Property of ProteoGenix and made in the course of providing the service ("Improvements to the Property of ProteoGenix") are the exclusive property of ProteoGenix and are not included in the rights transferred to the client.
6. All intellectual property rights of any type, nature, and description, including but not limited to all results, antibody libraries, and all antibody sequences they contain, cell lines, vectors, gene constructs, reagents, formulas, inventions, patents, know-how, and technologies of ProteoGenix existing prior to any order, are and remain the exclusive property of ProteoGenix.

XII - COMPLIANCE WITH APPLICABLE REGULATIONS

1. The client declares and warrants that they fully comply with all applicable national and international laws and regulations, currently in force or in the future, including those related to the use and export of the products.
2. In the event of a violation by the client of any of these laws or regulations, as well as in the case of an investigation into an alleged violation, the client undertakes to promptly take all necessary measures to remedy this violation.
   The client will bear all consequences resulting from such a violation, and ProteoGenix shall not be held responsible.

XIII - MISCELLANEOUS

These general terms and conditions of sale are governed by and construed in accordance with French law.
Any dispute regarding the interpretation and execution of these general terms and conditions of sale, as well as the sale of the products and services to which they apply, will be under the exclusive jurisdiction of the judicial court of Strasbourg.
The company PROTEOGENIX has its registered office at 19 rue de la Haye, 67300 Schiltigheim.